GRCE (Grace Therapeutics) EBIT per Share : $-1.54 (TTM As of Dec. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Grace Therapeutics EBIT per Share?

Grace Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was $-0.32. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.54.

During the past 3 years, the average EBIT per Share Growth Rate was 29.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was 44.50% per year. During the past 10 years, the average EBIT per Share Growth Rate was 32.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Grace Therapeutics's EBIT per Share or its related term are showing as below:

GRCE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -22.8 Med: 12.8 Max: 56.2
Current: 29.4

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Grace Therapeutics was 56.20% per year. The lowest was -22.80% per year. And the median was 12.80% per year.

GRCE's 3-Year EBIT Growth Rate is ranked better than
74.9% of 1235 companies
in the Biotechnology industry
Industry Median: 8 vs GRCE: 29.40

Grace Therapeutics's EBIT for the three months ended in Dec. 2024 was $-3.70 Mil.

Grace Therapeutics EBIT per Share Historical Data

The historical data trend for Grace Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grace Therapeutics EBIT per Share Chart

Grace Therapeutics Annual Data

Trend

Feb14

Feb15

Feb16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT per Share

Get a 7-Day Free Trial

-14.34

-4.34

-2.50

-2.45

-1.53

Grace Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.26	-0.35	-0.45	-0.42	-0.32

Grace Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Grace Therapeutics's EBIT per Share for the fiscal year that ended in Mar. 2024 is calculated as

	EBIT per Share		(A: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.367	/	7.436
=	-1.53

Grace Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-3.704	/	11.506
=	-0.32

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.54

Grace Therapeutics (NAS:GRCE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Grace Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Grace Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Grace Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Grace Therapeutics Inc (NAS:GRCE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540

Website

https://www.acastipharma.com

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Executives

George Kottayil	director	49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis	director	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren	director	282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru	director	11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds	director	545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar	officer: VP Program Management	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea	officer: VP Clinical Operations	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli	officer: Chief Executive Officer	206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald	officer: Chief Medical Officer	200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby	director	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine	director
Rajitha Grace 2018 Irrevocable Trust	10 percent owner	40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer	10 percent owner	20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford	officer: CHIEF FINANCIAL OFFICER	3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan	director	C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202